Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses

基于结构的T细胞疫苗设计,用于SARS-CoV-2变异株和沙贝病毒

阅读:3
作者:Anusha Nathan ,Elizabeth J Rossin ,Clarety Kaseke ,Ryan J Park ,Ashok Khatri ,Dylan Koundakjian ,Jonathan M Urbach ,Nishant K Singh ,Arman Bashirova ,Rhoda Tano-Menka ,Fernando Senjobe ,Michael T Waring ,Alicja Piechocka-Trocha ,Wilfredo F Garcia-Beltran ,A John Iafrate ,Vivek Naranbhai ,Mary Carrington ,Bruce D Walker ,Gaurav D Gaiha

Abstract

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants that escape convalescent and vaccine-induced antibody responses has renewed focus on the development of broadly protective T-cell-based vaccines. Here, we apply structure-based network analysis and assessments of HLA class I peptide stability to define mutationally constrained CD8+ T cell epitopes across the SARS-CoV-2 proteome. Highly networked residues are conserved temporally among circulating variants and sarbecoviruses and disproportionately impair spike pseudotyped lentivirus infectivity when mutated. Evaluation of HLA class I stabilizing activity for 18 globally prevalent alleles identifies CD8+ T cell epitopes within highly networked regions with limited mutational frequencies in circulating SARS-CoV-2 variants and deep-sequenced primary isolates. Moreover, these epitopes elicit demonstrable CD8+ T cell reactivity in convalescent individuals but reduced recognition in recipients of mRNA-based vaccines. These data thereby elucidate key mutationally constrained regions and immunogenic epitopes in the SARS-CoV-2 proteome for a global T-cell-based vaccine against emerging variants and SARS-like coronaviruses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。